comprehensive -WSS

comprehensive

author：leisure time 2025-10-01 12:35:19 - browse：22

Adam's take main illustration — Molly Ferguson/STAT

Behind the stellar commercial launch of Amylyx Pharmaceuticals’ treatment for ALS lies an uncomfortable question: Does early success of the drug, called Relyvrio, make it more complicated, perhaps impossible, to pull it from the market if we find out next year that it doesn’t work?

On Monday night, Amylyx said Relyvrio sales totaled $22 million in 2022 — a period that covers slightly more than one calendar quarter given the drug’s U.S. approval last September. The company said approximately 1,300 ALS patients were on Relyvrio at the end of December, and it expects that number to at least double by the end of the first quarter.

“We’re probably going to double, closer to triple, our revenue in Q1,” said James Frates, Amylyx’s chief financial officer, speaking on Monday night’s conference call.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Type 2 diabetes prevention programs work at large scale: study

WSS

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

Publishing genetic code of viruses could cause disaster

Cholera vaccine supplies dangerously low, outbreaks surging

Readout Newsletter: Beam, Prozac, "TechBio" and more

CVS, Rite Aid closures threaten to worsen pharmacy deserts

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

Wikipedia

comprehensive

entertainment

Wildfire smoke exposes gaps in outdoor worker protections

CDC panel: People 65 and older should get a Covid spring booster shot

Anesthesiologist group: stop taking Ozempic before surgery

Elisabeth Bik tackles the widespread issue of research misconduct

DIEP, the 'gold standard' of breast reconstruction, is under threat

Type 2 diabetes prevention programs work at large scale: study

Moonlake's readout produced a cash windfall. Risks remain

Children’s Hospital revives plan for pedestrian bridge

Walensky prepares to leave CDC — and Congress — behind

Carbon Health diabetes program, a test of data

hotspot

Medical school prerequisites are outdated

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

NEJM study measures Covid brain fog, impact on IQ

Pfizer is about to make a big push in cancer. Will investors listen?

How state and local governments are sidelining science

White House drug czar issues call for 'recovery

hotspot

leisure time

focus

explore